A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.

Youness Lagoubi Mohamed Tahar Sfar Jorge A Gomez

Published in: Human vaccines & immunotherapeutics (2022)

and NTHi in Tunisia. PHiD-CV is more cost-effective than PCV13, generating similar health benefits, at a reduced net cost of almost $1 million USD per vaccinated cohort.

Keyphrases

quality improvement
public health
healthcare
mental health
health information
health promotion
human health
risk assessment